Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 166

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 166
---
 Income from Operations before Provision for Income Taxes 
     (1,147.79) 
     405.06 
  
    Provision for Income Taxes 
     0.04  
     0.06 
  
    Net (Loss) Income including Noncontrolling Interest 
     (1,147.83) 
     405.01 
  
    Net Loss – Noncontrolling Interest 
     (0.46) 
     (2.35)
  
    Net (Loss) Income – attributed to 60 Degrees Pharmaceuticals, Inc. 
     (1,147.37)% 
     407.36%

28

Comparison of the Three Months Ended March
31, 2025 and 2024

Product Revenues - net of Discounts and
Rebates, Cost of Revenues, Gross Profit, and Gross Margin

    For the Three Months Ended March 31,  

    Consolidated Statements of Operations Data: 
    2025  
    2024  
    $ Change  
    % Change 
  
    Product Revenues – net of Discounts and Rebates 
    $163,552  
    $105,674  
    $57,878  
     54.77%
  
    Cost of Revenues 
     73,272  
     65,437  
     7,835  
     11.97 
  
    Gross Profit 
    $90,280  
    $40,237  
    $50,043  
     124.37%
  
    Gross Margin % 
     55.20% 
     38.08% 

Product Revenues - net of Discounts and Rebates

Our product revenues - net of discounts and rebates were $163,552 for
the three months ended March 31, 2025, as compared to $105,674 for the three months ended March 31, 2024. For the three months ended March
31, 2025, our U.S. pharmaceutical distributor and Infuserve America accounted for 85% and 6% of our total net product sales of Arakoda,
respectively, and Kodatef sales to our Australian distributor accounted for 9% of total net product sales (99%, 0%, and 1% for the three
months ended March 31, 2024, respectively). Domestic, commercial product sales are primarily driving increased sales volume during the